

## **Product** Data Sheet

## **Anzurstobart**

**Cat. No.:** HY-P990033 **CAS No.:** 2543693-10-1

Target: Others
Pathway: Others

**Storage:** Please store the product under the recommended conditions in the Certificate of Analysis.

## **BIOLOGICAL ACTIVITY**

Description	Anzurstobart (CC-95251; BMS-986351) is a high-affinity, fully human monoclonal anti-SIRP $\alpha$ antibody that blocks the binding of CD47 to SIRP $\alpha$ . Anzurstobart enhances macrophage phagocytic activity against DLBCL cell lines in co-culture models when combined with the antibody Rituximab (HY-P9913). Anzurstobart has the potential for solid and hematologic malignancies research <sup>[1]</sup> .
IC <sub>50</sub> & Target	SIRPα

## **REFERENCES**

[1]. Henry Chan, et al. Discovery and Preclinical Characterization of CC-95251, an Anti-SIRPa Antibody That Enhances Macrophage-Mediated Phagocytosis of Non-Hodgkin Lymphoma (NHL) Cells When Combined with Rituximab. Blood (2021) 138 (Supplement 1): 2271.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Inhibitors • Screening Libraries

s • Proteins

Page 1 of 1